OncLive TV

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Suneel Kamath, MD, discusses the importance of including underrepresented patient populations in clinical trials.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Alexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.

Bradley J. Monk, MD, FACS, FACOG, discusses the role platinum-based chemotherapy in recurrent ovarian cancer, plus emerging antibody-drug conjugates in the space.

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Shahneen Sandhu, MD, discusses the safety data seen in the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.